Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

BECEIVED. SECRETARY OF THE SENATE

00 AUG 14 PH 3:12

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

t. Registrant Name Williams & Jensen, PC	P P P P P P P P P P P P P P P P P P P	
Z. Address Check if different than previously reported 1155 21st Street, NW Washington Suite 306 DC 20036		
Principal Place of Business (if different from line 2)     Should be a Common of the Common of		
City State/Zip (or Constry)  4. Contast Name February  Barbara W. Bonfiglio 202-659-8201	1 (optional) 5. Senate ID # 41454-924	
7. Client Name  Self AstraZeneca Pharmaceuticals Group(formerly Zeneca)	6. House ID 6 30771057	
TYPE OF REPORT 8. Year 2000 Midyear st.  Check if this filing amends a previously filed version of thi  Check if this is a Termination Report □ >> Termination  INCOME OR EXPENSES - Complete Either	s report   II. No Lobbying Activity	
12. Lobbying Firms		
ENCOME relating to lobbying activities for this reporting period was:  Less than \$10,000   \$10,000 or more	EXPENSES relating to lobbying activities for this reporting period were:  i.ess than \$10,000 []  \$10,000 or more [] >> \$  Expenses (nearen \$20,000) []  14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
	■ Method A. Reporting amounts using LDA definitions only      ■ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code      ■ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	
ignature	Date <u>\$/14/2000</u>	
rinted Name and Title Borbara W. Bonfiglio - attorney	Page 1 of 3	

	Williams & Jensen, PC		
ient Name:	AstraZeneca Pharmaceuticals Group(	formerły Zeneca)	
gaged in lobbyi		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide I.	
General issue     Specific Lob     Prescription			
	Congress and Federal agencies contacted presentatives	.  Check if None	
8. Name of eac	ι indivídual who acted as a lobbyíst in this	issue area  Covered Official Position (if applicable)	New
8. Name of eac Olsen, Gcor	Name		New No
	Name ge G.		
Olsen, Geor	Name ge G.	Covered Official Position (if applicable)	No
Olsen, Geor Marquis, Ly	Name ge G.	Covered Official Position (if applicable)  Legislative Director for Gary Condit	No

ş⊷		
Registrant Name:	Williams & Jensen, PC	
Hient Name:	AstraZeneca Pharmaceuticals Group(formerly Zeneca)	
ngaged in lobbyír	TIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant of on behalf of the client during the reporting period. Using a separate page for each code, provide rested. Attach additional page(s) as needed.	
General issue     Specific Lobi     Fetal tissue i     Drug Prices	ying issues	
17. House(s) of C Senate House of Re	Congress and Federal agencies contacted   C) Check if None  presentatives	
8. Name of each	individual who acted as a lobbyist in this issue area  Name  Covered Official Position (if applicable)	New
Olsen, Georg	e.G.	No
		·
t9. Interest of each	th foreign entity in the specific issues tisted on line 16 above	